ALK and non-small cell lung carcinoma: Genetic‐based therapies comprise treatments that address a common driver mutations (Epithelioma Growth Factor Receptor = EGFR mutation) seen in 11% of NSCLC tumors and ALK (Anaplastic lymphoma Kinase) translocations in 5%.7 The EGFR inhibitors have received approval from the results of randomized trials demonstrating a benefit on improved progression‐free survival (PFS) and objective response rate (ORR).8, 9, 10, 11, 12 New immunotherapies, known as immune checkpoint inhibitors, have also played an integral role in advancing outcomes for patients with advanced NSCLC in recent years.